2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 01:23, 12 December 2023
, 12 December 2023→Clinical Trials
(→Todo) |
|||
| Line 219: | Line 219: | ||
|- | |- | ||
|{{pmid_text|31685720}} | |{{pmid_text|31685720}} | ||
| | |singe admission | ||
* | *up to 500 mg | ||
| | | | ||
*10 healthy men | *10 healthy men | ||
| Line 318: | Line 317: | ||
| | | | ||
* NAD+ levels increase by 11.3% after 30 days, 38% after 60 days | * NAD+ levels increase by 11.3% after 30 days, 38% after 60 days | ||
|- | |||
|{{pmid text|36225528}} | |||
|single intravenous administration | |||
* 300 mg | |||
| | |||
* 10 healthy adults | |||
* age 20-70 | |||
| | |||
* 300 mg intravenous NMN administration is tolerated by humans | |||
* significantly increased blood NAD+ levels | |||
|- | |- | ||
|{{pmid_text|36482258}} | |{{pmid_text|36482258}} | ||
| Line 379: | Line 389: | ||
* 250 mg of NMN for 12 weeks does not significantly reduce artery stiffness — a risk factor for cardiovascular disease, dementia, and death — in healthy middle-aged adults. | * 250 mg of NMN for 12 weeks does not significantly reduce artery stiffness — a risk factor for cardiovascular disease, dementia, and death — in healthy middle-aged adults. | ||
* However, NMN reduces artery stiffness in individuals with high blood-glucose and body mass index (weight/height). | * However, NMN reduces artery stiffness in individuals with high blood-glucose and body mass index (weight/height). | ||
* Blood vessel biological aging is reversed by 2 years with NMN treatment. | * Blood vessel biological aging is reversed by 2 years with NMN treatment. | ||
|- | |- | ||
|{{pmid text|36443648}} | |{{pmid text|36443648}} | ||